Protalix BioTherapeutics (NYSE:PLX) Upgraded at StockNews.com

StockNews.com upgraded shares of Protalix BioTherapeutics (NYSE:PLX – Free Report) from a hold rating to a buy rating in a report published on Thursday. Several other research firms also recently commented on PLX. HC Wainwright reaffirmed a buy rating and set a $10.00 price objective on shares of Protalix BioTherapeutics in a research note on […]

Related Keywords

Canada ,Brazil ,Lido ,Estado Do Rio ,Australia ,Russia ,United States ,Israel ,Turkey ,California ,Dror Bashan ,Protalix Biotherapeutics ,Virtu Financial ,Barclays Plc ,Securities Exchange Commission ,Lido Advisors ,Aptus Capital Advisors ,Protalix Biotherapeutics Inc ,Free Report ,Get Free Report ,Exchange Commission ,Capital Advisors ,California State Teachers Retirement System ,Nyse Plx ,Mplx ,Medical ,Upgrade ,Stocknews Com ,